ClinicalTrials.gg
CompletedNCT05649137Updated Apr 27, 2026Results posted

A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight

A Phase 3 interventional study of Semaglutide and Semaglutide in Obesity and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 76 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
512
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 143 studies testing semaglutide in Obesity — 68 open to participants now, 77 under way, 14 of them phase 3. Semaglutide · Obesity.

Enrollment
14th of 143
512 · median 100
Started
2023
with 14 others
Phase 3
42 of 143
10 open now
Registered
56th of 143
by date
Lead sponsor
41 of 143
Novo Nordisk A/S

Among the 143 studies testing semaglutide in Obesity, this one is the 14th largest by enrollment, is one of 15 that started in 2023, is one of 42 in phase 3, and was the 56th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

68 of the 143 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

63 more — sign in →

By country, each count listing its studies:

All 68 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 143 studies testing semaglutide in Obesity, or all of them as a file.
02

Study summary

This study will look at how much weight participants will lose and how much blood sugar control they achieve from the start to the end of the study. The weight loss in participants taking the investigational high dose of semaglutide will be compared to the weight loss in people taking "dummy" medicine and a lower dose of semaglutide. In addition to taking the medicine, participants will have talks with study staff about healthy food choices and how to be more physically active. Participants will either get semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. Participants are more likely (4 out of 5) to get semaglutide than the "dummy" medicine. The study medicine will be injected briefly, under skin, with a thin needle, typically in the stomach, thighs, or upper arms. After receiving first dose, the dose of semaglutide will be gradually increased until reaching the target dose. The study will last for about 1.5 years

03

Conditions studied

  • Obesity
  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female.
  • Age above or equal to 18 years at the time of signing .
  • greater than or equal to 30.0 kilograms per square meter (kg/m\^2).
  • Diagnosed with type 2 diabetes (T2D) greater than or equal to 180 days prior to the day of screening.
  • History of at least one self-reported unsuccessful dietary effort to lose body weight.
  • 7.0-10.0 percent (53-86 millimoles per mole [mmol/mol]) (both inclusive) as measured by central laboratory at screening.

Exclusion criteria

Exclusion Criteria:

  • A self-reported change in body weight greater than 5 kilograms (kg) (11 pounds [lbs]) within 90 days before screening irrespective of medical records.
  • Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma.
  • Renal impairment with estimated (eGFR) less than 30 milliliters per minute per 1.73 square meter (30 mL/min/1.73 m\^2) (less than 45 mL/min/1.73 m\^2 in participants treated with Sodium-glucose Cotransporter-2 [SGLT2i]) according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation as defined by Kidney Disease: Improving Global Outcomes (KDIGO) 2012 by the central laboratory at screening.
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomization. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
512 participants (actual)

Study arms

  • Experimental
    Semaglutide 7.2 mg

    Participants will receive once-weekly injection of semaglutide subcutaneously (s.c.) in 20 week dose escalation period with dose escalation (0.25 milligram \[mg\], 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and 7.2 mg) every fourth week. Treatment will be continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks until week 72.

    Drug: Semaglutide

  • Experimental
    Semaglutide 2.4 mg

    Participants will receive once-weekly s.c. injection of semaglutide in 20 week dose escalation period with dose escalation (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week until maintenance dose of 2.4 mg of semaglutide was reached. Treatment will be continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 72.

    Drug: Semaglutide

  • Placebo comparator
    Placebo

    Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks.

    Drug: Placebo

Interventions

  • Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg and 7.2 mg) every fourth week. Treatment will be continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.

  • Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week. Treatment will be continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.

  • DrugPlacebo

    Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.

06

What researchers measure

Primary outcomes

  1. Relative Change in Body Weight

    Relative change in body weight from baseline (week 0) to end of treatment (week 72) is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  2. Number of Participants Who Achieve Body Weight Reduction Greater Than or Equal to (>=) 5% (Yes/no)

    Number of participants who achieve body weight reduction \>=5% is presented. Yes defines participants who achieved body weight reduction \>= 5% and No defines participants who did not achieve body weight reduction \>=5%.

    Time frame: At week 72

Secondary outcomes

  1. Number of Participants Who Achieve Body Weight Reduction >= 10% (Yes/no)

    Number of participants who achieve body weight reduction \>=10% is presented. Yes defines participants who achieved body weight reduction greater than or equal to 10% and No defines participants who did not achieve body weight reduction greater than or equal to 10%.

    Time frame: At week 72

  2. Number of Participants Who Achieve Body Weight Reduction >= 15% (Yes/no)

    Number of participants who achieve body weight reduction \>=15% is presented. Yes defines participants who achieved body weight reduction greater than or equal to 15% and No defines participants who did not achieve body weight reduction greater than or equal to 15%.

    Time frame: At week 72

  3. Number of Participants Who Achieve Body Weight Reduction >= 20% (Yes/no)

    Number of participants who achieve body weight reduction \>=20% is presented. Yes defines participants who achieved body weight reduction greater than or equal to 20% and No defines participants who did not achieve body weight reduction greater than or equal to 20%.

    Time frame: At week 72

  4. Change in Waist Circumference

    Change in waist circumference from baseline (week 0) to end of treatment (week 72) is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  5. Change in Glycated Haemoglobin (HbA1c)

    Change in HbA1c from baseline (week 0) to end of treatment (week 72) is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  6. Change in Body Weight

    Change in body weight from baseline (week 0) to end of treatment (week 72) is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  7. Change in Body Mass Index (BMI)

    Change in BMI from baseline (week 0) to end of treatment (week 72) is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  8. Change in Systolic Blood Pressure

    Change in systolic blood pressure from baseline (week 0) to end of treatment (week 72) is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  9. Change in Diastolic Blood Pressure

    Change in diastolic blood pressure from baseline (week 0) to end of treatment (week 72) is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  10. Change in Total Cholesterol (Millimoles Per Liter [mmol/L]) - Ratio to Baseline

    Change in total cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  11. Change in Total Cholesterol (Milligrams Per Deciliter [mg/dL]) - Ratio to Baseline

    Change in total cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  12. Change in High-density Lipoprotein (HDL) Cholesterol (mmol/L) - Ratio to Baseline

    Change in HDL cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  13. Change in HDL Cholesterol (mg/dL) - Ratio to Baseline

    Change in HDL cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  14. Change in Low-density Lipoprotein (LDL) Cholesterol (mmol/L) - Ratio to Baseline

    Change in LDL cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  15. Change in LDL Cholesterol (mg/dL) - Ratio to Baseline

    Change in LDL cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  16. Change in Very-low-density Lipoprotein (VLDL) Cholesterol (mmol/L) - Ratio to Baseline

    Change in VLDL cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  17. Change in VLDL Cholesterol (mg/dL) - Ratio to Baseline

    Change in VLDL cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  18. Change in Triglycerides (mmol/L) - Ratio to Baseline

    Change in triglycerides in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  19. Change in Triglycerides (mg/dL) - Ratio to Baseline

    Change in triglycerides in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  20. Change in Free Fatty Acids (mmol/L) - Ratio to Baseline

    Change in free fatty acids in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  21. Change in Free Fatty Acids (mg/dL) - Ratio to Baseline

    Change in free fatty acids in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  22. Change in High-sensitivity C-reactive Protein (hsCRP) - Ratio to Baseline

    Change in hsCRP in mg/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  23. Change in Fasting Plasma Glucose

    Change in fasting plasma glucose from baseline (week 0) to end of treatment (week 72) is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  24. Change in Fasting Serum Insulin (Picomoles Per Liter [Pmol/L]) - Ratio to Baseline

    Change in fasting serum insulin in pmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  25. Change in Fasting Serum Insulin (Milliinternational Units Per Milliliter [mIU/mL]) - Ratio to Baseline

    Change in fasting serum insulin in mIU/ml from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  26. Number of Participants With HbA1c Less Than 7.0 % (53 Millimoles Per Mole [mmol/Mol])

    Number of participants with HbA1c less than 7.0 % (53 mmol/mol) at week 72 is presented.

    Time frame: At week 72

  27. Number of Participants With HbA1c Less Than or Equal to 6.5% (48 mmol/Mol)

    Number of participants with HbA1c less than or equal to 6.5% (48 mmol/mol) at week 72 is presented.

    Time frame: At week 72

  28. Semaglutide 7.2 mg Versus Placebo: Number of Adverse Events (AEs)

    Number of AEs is reported. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP.

    Time frame: At week 81

  29. Semaglutide 7.2 mg Versus Placebo: Number of Serious Adverse Events (SAEs)

    Number of SAEs is reported. A SAE is any untoward medical occurrence that fulfils at least one of the following criteria: results in death, is life threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or important medical event.

    Time frame: At week 81

  30. Change in Pulse

    Change in pulse from baseline (week 0) to end of treatment (week 72) is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  31. Semaglutide 7.2 mg Versus Placebo: Number of Treatment Emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes

    Number of treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes is presented.

    Time frame: At week 81

  32. Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of AEs

    Number of AEs is reported. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of IMP, whether or not considered related to the IMP.

    Time frame: At week 81

  33. Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of SAEs

    Number of SAEs is reported. A SAE is any untoward medical occurrence that fulfils at least one of the following criteria: results in death, is life threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or important medical event.

    Time frame: At week 81

  34. Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of Treatment Emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes

    Number of treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes is presented.

    Time frame: At week 81

07

Results

Posted Apr 27, 2026

Participant flow

The trial was conducted at 68 sites in 8 countries.

Participant flow — Overall Study
MilestoneSemaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
Started307103102
Full analysis set307103102
Safety analysis set307103102
Completed29510096
Not completed1236
Withdrew: Withdrawal by subject503
Withdrew: Lost to follow-up202
Withdrew: Physician decision110
Withdrew: Death411
Withdrew: Unspecified reason010

Outcome measures

PrimaryRelative Change in Body Weight

Relative change in body weight from baseline (week 0) to end of treatment (week 72) is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Mean · Percentage (%) change in body weight
Relative Change in Body Weight
Percentage (%) change in body weightSemaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
Relative Change in Body Weight-13.5 ± 8.7-10.7 ± 8.1-4.0 ± 6.2
Statistical analysis
  • Semaglutide 7.2 mg vs Placebo · ANCOVA · p = <0.0001 · Treatment difference: -9.33 · 95% CI -10.95 to -7.71
PrimaryNumber of Participants Who Achieve Body Weight Reduction Greater Than or Equal to (>=) 5% (Yes/no)

Number of participants who achieve body weight reduction \>=5% is presented. Yes defines participants who achieved body weight reduction \>= 5% and No defines participants who did not achieve body weight reduction \>=5%.

Time frame:
At week 72
Reported as:
Count of participants · Participants
Number of Participants Who Achieve Body Weight Reduction Greater Than or Equal to (>=) 5% (Yes/no)
ParticipantsSemaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
Yes2517333
No402462
Statistical analysis
  • Semaglutide 7.2 mg vs Placebo · Binary regression model · p = <0.0001 · Odds ratio (or): 10.03 · 95% CI 5.96 to 16.87
SecondaryNumber of Participants Who Achieve Body Weight Reduction >= 10% (Yes/no)

Number of participants who achieve body weight reduction \>=10% is presented. Yes defines participants who achieved body weight reduction greater than or equal to 10% and No defines participants who did not achieve body weight reduction greater than or equal to 10%.

Time frame:
At week 72
Reported as:
Count of participants · Participants
Number of Participants Who Achieve Body Weight Reduction >= 10% (Yes/no)
ParticipantsSemaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
Yes1835011
No1084784
SecondaryNumber of Participants Who Achieve Body Weight Reduction >= 15% (Yes/no)

Number of participants who achieve body weight reduction \>=15% is presented. Yes defines participants who achieved body weight reduction greater than or equal to 15% and No defines participants who did not achieve body weight reduction greater than or equal to 15%.

Time frame:
At week 72
Reported as:
Count of participants · Participants
Number of Participants Who Achieve Body Weight Reduction >= 15% (Yes/no)
ParticipantsSemaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
Yes120287
No1716988
SecondaryNumber of Participants Who Achieve Body Weight Reduction >= 20% (Yes/no)

Number of participants who achieve body weight reduction \>=20% is presented. Yes defines participants who achieved body weight reduction greater than or equal to 20% and No defines participants who did not achieve body weight reduction greater than or equal to 20%.

Time frame:
At week 72
Reported as:
Count of participants · Participants
Number of Participants Who Achieve Body Weight Reduction >= 20% (Yes/no)
ParticipantsSemaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
Yes62142
No2298393
SecondaryChange in Waist Circumference

Change in waist circumference from baseline (week 0) to end of treatment (week 72) is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Mean · Centimeters (cm)
Change in Waist Circumference
Centimeters (cm)Semaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
Change in Waist Circumference-12.6 ± 10.5-10.6 ± 8.4-6.5 ± 10.6
SecondaryChange in Glycated Haemoglobin (HbA1c)

Change in HbA1c from baseline (week 0) to end of treatment (week 72) is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Mean · Percentage of HbA1c
Change in Glycated Haemoglobin (HbA1c)
Percentage of HbA1cSemaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
Change in Glycated Haemoglobin (HbA1c)-1.8 ± 1.2-1.7 ± 1.0-0.3 ± 1.3
SecondaryChange in Body Weight

Change in body weight from baseline (week 0) to end of treatment (week 72) is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Mean · Kilograms (kg)
Change in Body Weight
Kilograms (kg)Semaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
Change in Body Weight-14.9 ± 10.6-11.4 ± 8.9-4.6 ± 7.1
SecondaryChange in Body Mass Index (BMI)

Change in BMI from baseline (week 0) to end of treatment (week 72) is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Mean · kilograms per meter square (kg/m^2)
Change in Body Mass Index (BMI)
kilograms per meter square (kg/m^2)Semaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
Change in Body Mass Index (BMI)-5.3 ± 3.8-4.1 ± 3.3-1.6 ± 2.5
SecondaryChange in Systolic Blood Pressure

Change in systolic blood pressure from baseline (week 0) to end of treatment (week 72) is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Mean · Millimeters of mercury (mmHg)
Change in Systolic Blood Pressure
Millimeters of mercury (mmHg)Semaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
Change in Systolic Blood Pressure-8 ± 13-7 ± 15-3 ± 13
SecondaryChange in Diastolic Blood Pressure

Change in diastolic blood pressure from baseline (week 0) to end of treatment (week 72) is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Mean · mmHg
Change in Diastolic Blood Pressure
mmHgSemaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
Change in Diastolic Blood Pressure-3 ± 9-3 ± 10-3 ± 9
SecondaryChange in Total Cholesterol (Millimoles Per Liter [mmol/L]) - Ratio to Baseline

Change in total cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Geometric mean · Ratio of total cholesterol
Change in Total Cholesterol (Millimoles Per Liter [mmol/L]) - Ratio to Baseline
Ratio of total cholesterolSemaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
Change in Total Cholesterol (Millimoles Per Liter [mmol/L]) - Ratio to Baseline0.96 ± 23.00.96 ± 21.10.97 ± 28.3
SecondaryChange in Total Cholesterol (Milligrams Per Deciliter [mg/dL]) - Ratio to Baseline

Change in total cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Geometric mean · Ratio of total cholesterol
Change in Total Cholesterol (Milligrams Per Deciliter [mg/dL]) - Ratio to Baseline
Ratio of total cholesterolSemaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
Change in Total Cholesterol (Milligrams Per Deciliter [mg/dL]) - Ratio to Baseline0.96 ± 23.00.96 ± 21.10.97 ± 28.3
SecondaryChange in High-density Lipoprotein (HDL) Cholesterol (mmol/L) - Ratio to Baseline

Change in HDL cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Geometric mean · Ratio of HDL cholesterol
Change in High-density Lipoprotein (HDL) Cholesterol (mmol/L) - Ratio to Baseline
Ratio of HDL cholesterolSemaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
Change in High-density Lipoprotein (HDL) Cholesterol (mmol/L) - Ratio to Baseline1.10 ± 17.81.06 ± 13.51.07 ± 16.1
SecondaryChange in HDL Cholesterol (mg/dL) - Ratio to Baseline

Change in HDL cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Geometric mean · Ratio of HDL cholesterol
Change in HDL Cholesterol (mg/dL) - Ratio to Baseline
Ratio of HDL cholesterolSemaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
Change in HDL Cholesterol (mg/dL) - Ratio to Baseline1.10 ± 17.81.06 ± 13.51.07 ± 16.1
SecondaryChange in Low-density Lipoprotein (LDL) Cholesterol (mmol/L) - Ratio to Baseline

Change in LDL cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Geometric mean · Ratio of LDL cholesterol
Change in Low-density Lipoprotein (LDL) Cholesterol (mmol/L) - Ratio to Baseline
Ratio of LDL cholesterolSemaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
Change in Low-density Lipoprotein (LDL) Cholesterol (mmol/L) - Ratio to Baseline0.99 ± 40.10.95 ± 36.50.97 ± 41.4
SecondaryChange in LDL Cholesterol (mg/dL) - Ratio to Baseline

Change in LDL cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Geometric mean · Ratio of LDL cholesterol
Change in LDL Cholesterol (mg/dL) - Ratio to Baseline
Ratio of LDL cholesterolSemaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
Change in LDL Cholesterol (mg/dL) - Ratio to Baseline0.99 ± 40.10.95 ± 36.50.97 ± 41.4
SecondaryChange in Very-low-density Lipoprotein (VLDL) Cholesterol (mmol/L) - Ratio to Baseline

Change in VLDL cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Geometric mean · Ratio of VLDL cholesterol
Change in Very-low-density Lipoprotein (VLDL) Cholesterol (mmol/L) - Ratio to Baseline
Ratio of VLDL cholesterolSemaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
Change in Very-low-density Lipoprotein (VLDL) Cholesterol (mmol/L) - Ratio to Baseline0.72 ± 42.50.81 ± 40.40.90 ± 47.8
SecondaryChange in VLDL Cholesterol (mg/dL) - Ratio to Baseline

Change in VLDL cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Geometric mean · Ratio of VLDL cholesterol
Change in VLDL Cholesterol (mg/dL) - Ratio to Baseline
Ratio of VLDL cholesterolSemaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
Change in VLDL Cholesterol (mg/dL) - Ratio to Baseline0.72 ± 42.50.81 ± 40.40.90 ± 47.8
SecondaryChange in Triglycerides (mmol/L) - Ratio to Baseline

Change in triglycerides in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Geometric mean · Ratio of triglycerides
Change in Triglycerides (mmol/L) - Ratio to Baseline
Ratio of triglyceridesSemaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
Change in Triglycerides (mmol/L) - Ratio to Baseline0.71 ± 46.20.80 ± 42.20.87 ± 54.4
SecondaryChange in Triglycerides (mg/dL) - Ratio to Baseline

Change in triglycerides in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Geometric mean · Ratio of triglycerides
Change in Triglycerides (mg/dL) - Ratio to Baseline
Ratio of triglyceridesSemaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
Change in Triglycerides (mg/dL) - Ratio to Baseline0.71 ± 46.20.80 ± 42.20.87 ± 54.4
SecondaryChange in Free Fatty Acids (mmol/L) - Ratio to Baseline

Change in free fatty acids in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Geometric mean · Ratio of free fatty acids
Change in Free Fatty Acids (mmol/L) - Ratio to Baseline
Ratio of free fatty acidsSemaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
Change in Free Fatty Acids (mmol/L) - Ratio to Baseline0.74 ± 69.80.81 ± 70.60.98 ± 65.8
SecondaryChange in Free Fatty Acids (mg/dL) - Ratio to Baseline

Change in free fatty acids in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Geometric mean · Ratio of free fatty acids
Change in Free Fatty Acids (mg/dL) - Ratio to Baseline
Ratio of free fatty acidsSemaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
Change in Free Fatty Acids (mg/dL) - Ratio to Baseline0.74 ± 69.80.81 ± 70.60.98 ± 65.8
SecondaryChange in High-sensitivity C-reactive Protein (hsCRP) - Ratio to Baseline

Change in hsCRP in mg/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Geometric mean · Ratio of hsCRP
Change in High-sensitivity C-reactive Protein (hsCRP) - Ratio to Baseline
Ratio of hsCRPSemaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
Change in High-sensitivity C-reactive Protein (hsCRP) - Ratio to Baseline0.47 ± 166.70.48 ± 121.10.82 ± 96.0
SecondaryChange in Fasting Plasma Glucose

Change in fasting plasma glucose from baseline (week 0) to end of treatment (week 72) is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Mean · mg/dL
Change in Fasting Plasma Glucose
mg/dLSemaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
Change in Fasting Plasma Glucose-59.6 ± 53.1-58.4 ± 46.3-20.2 ± 68.7
SecondaryChange in Fasting Serum Insulin (Picomoles Per Liter [Pmol/L]) - Ratio to Baseline

Change in fasting serum insulin in pmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Geometric mean · Ratio of fasting serum insulin
Change in Fasting Serum Insulin (Picomoles Per Liter [Pmol/L]) - Ratio to Baseline
Ratio of fasting serum insulinSemaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
Change in Fasting Serum Insulin (Picomoles Per Liter [Pmol/L]) - Ratio to Baseline0.77 ± 66.50.90 ± 70.60.87 ± 71.4
SecondaryChange in Fasting Serum Insulin (Milliinternational Units Per Milliliter [mIU/mL]) - Ratio to Baseline

Change in fasting serum insulin in mIU/ml from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Geometric mean · Ratio of fasting serum insulin
Change in Fasting Serum Insulin (Milliinternational Units Per Milliliter [mIU/mL]) - Ratio to Baseline
Ratio of fasting serum insulinSemaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
Change in Fasting Serum Insulin (Milliinternational Units Per Milliliter [mIU/mL]) - Ratio to Baseline0.77 ± 66.50.90 ± 70.60.87 ± 71.4
SecondaryNumber of Participants With HbA1c Less Than 7.0 % (53 Millimoles Per Mole [mmol/Mol])

Number of participants with HbA1c less than 7.0 % (53 mmol/mol) at week 72 is presented.

Time frame:
At week 72
Reported as:
Count of participants · Participants
Number of Participants With HbA1c Less Than 7.0 % (53 Millimoles Per Mole [mmol/Mol])
ParticipantsSemaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
Number of Participants With HbA1c Less Than 7.0 % (53 Millimoles Per Mole [mmol/Mol])2357527
SecondaryNumber of Participants With HbA1c Less Than or Equal to 6.5% (48 mmol/Mol)

Number of participants with HbA1c less than or equal to 6.5% (48 mmol/mol) at week 72 is presented.

Time frame:
At week 72
Reported as:
Count of participants · Participants
Number of Participants With HbA1c Less Than or Equal to 6.5% (48 mmol/Mol)
ParticipantsSemaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
Number of Participants With HbA1c Less Than or Equal to 6.5% (48 mmol/Mol)2096415
SecondarySemaglutide 7.2 mg Versus Placebo: Number of Adverse Events (AEs)

Number of AEs is reported. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP.

Time frame:
At week 81
Reported as:
Number · Events
Semaglutide 7.2 mg Versus Placebo: Number of Adverse Events (AEs)
EventsSemaglutide 7.2 mgPlacebo
Semaglutide 7.2 mg Versus Placebo: Number of Adverse Events (AEs)1581253
SecondarySemaglutide 7.2 mg Versus Placebo: Number of Serious Adverse Events (SAEs)

Number of SAEs is reported. A SAE is any untoward medical occurrence that fulfils at least one of the following criteria: results in death, is life threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or important medical event.

Time frame:
At week 81
Reported as:
Number · Events
Semaglutide 7.2 mg Versus Placebo: Number of Serious Adverse Events (SAEs)
EventsSemaglutide 7.2 mgPlacebo
Semaglutide 7.2 mg Versus Placebo: Number of Serious Adverse Events (SAEs)3921
SecondaryChange in Pulse

Change in pulse from baseline (week 0) to end of treatment (week 72) is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Mean · Beats per minute (bpm)
Change in Pulse
Beats per minute (bpm)Semaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
Change in Pulse1 ± 102 ± 10-4 ± 9
SecondarySemaglutide 7.2 mg Versus Placebo: Number of Treatment Emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes

Number of treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes is presented.

Time frame:
At week 81
Reported as:
Number · Episodes
Semaglutide 7.2 mg Versus Placebo: Number of Treatment Emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes
EpisodesSemaglutide 7.2 mgPlacebo
Semaglutide 7.2 mg Versus Placebo: Number of Treatment Emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes01
SecondarySemaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of AEs

Number of AEs is reported. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of IMP, whether or not considered related to the IMP.

Time frame:
At week 81
Reported as:
Number · Events
Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of AEs
EventsSemaglutide 7.2 mgSemaglutide 2.4 mg
Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of AEs1581508
SecondarySemaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of SAEs

Number of SAEs is reported. A SAE is any untoward medical occurrence that fulfils at least one of the following criteria: results in death, is life threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or important medical event.

Time frame:
At week 81
Reported as:
Number · Events
Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of SAEs
EventsSemaglutide 7.2 mgSemaglutide 2.4 mg
Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of SAEs3935
SecondarySemaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of Treatment Emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes

Number of treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes is presented.

Time frame:
At week 81
Reported as:
Number · Episodes
Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of Treatment Emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes
EpisodesSemaglutide 7.2 mgSemaglutide 2.4 mg
Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of Treatment Emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes00

Adverse events

Collected over From week 0 to week 81. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Semaglutide 7.2 mg4/307 (1.3%)30/307 (9.8%)187/307 (60.9%)
Semaglutide 2.4 mg1/103 (1%)11/103 (10.7%)64/103 (62.1%)
Placebo1/102 (1%)10/102 (9.8%)40/102 (39.2%)
Most frequent serious events
Showing 10 of 77
Most frequent serious events
EventSemaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
Atrial fibrillationCardiac disorders1/3072/1033/102
NephrolithiasisRenal and urinary disorders0/3072/1030/102
Acute kidney injuryRenal and urinary disorders0/3071/1031/102
AnaemiaBlood and lymphatic system disorders0/3070/1031/102
Aortic aneurysmVascular disorders0/3070/1031/102
Bell's palsyNervous system disorders0/3070/1031/102
Cardiac arrestCardiac disorders0/3070/1031/102
Carotid artery stenosisNervous system disorders0/3070/1031/102
Chest painGeneral disorders0/3070/1031/102
CholelithiasisHepatobiliary disorders0/3070/1031/102
Most frequent other events
Showing 10 of 17
Most frequent other events
EventSemaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
NauseaGastrointestinal disorders89/30729/10312/102
DiarrhoeaGastrointestinal disorders56/30721/1039/102
ConstipationGastrointestinal disorders45/30719/1035/102
VomitingGastrointestinal disorders51/30714/1033/102
Upper respiratory tract infectionInfections and infestations17/3079/1035/102
DyspepsiaGastrointestinal disorders25/3074/1032/102
NasopharyngitisInfections and infestations9/3073/1038/102
Decreased appetiteMetabolism and nutrition disorders21/3078/1035/102
EructationGastrointestinal disorders11/3078/1031/102
HeadacheNervous system disorders22/3078/1034/102

Baseline characteristics

Full analysis set included all randomised participants.

Age, Continuous
Age, Continuous(Years)Semaglutide 7.2 mgSemaglutide 2.4 mgPlaceboTotal
Mean57 ± 1058 ± 1055 ± 1056 ± 10
Sex: Female, Male
Sex: Female, Male(Participants)Semaglutide 7.2 mgSemaglutide 2.4 mgPlaceboTotal
Female1664752265
Male1415650247
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Semaglutide 7.2 mgSemaglutide 2.4 mgPlaceboTotal
Hispanic or Latino165829
Not Hispanic or Latino2919894483
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Semaglutide 7.2 mgSemaglutide 2.4 mgPlaceboTotal
American Indian or Alaska Native1001
Asian197632
Native Hawaiian or Other Pacific Islander5005
Black or African American2213944
White2588387428
More than one race2002
Unknown or Not Reported0000
08

Study locations

76 sites
  • Univ of Alabama Birmingham
    Birmingham, Alabama 35222, United States
  • Chambliss Clinical Trials, LLC
    Montgomery, Alabama 36106, United States
  • John Muir Physicians Network
    Concord, California 94520, United States
  • Velocity Clinical Research Westlake
    Los Angeles, California 90057, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • New West Physicians PC
    Golden, Colorado 80401, United States
  • ARS- Deland CRU
    DeLand, Florida 32720, United States
  • Jacksonville Ctr for Clin Res
    Jacksonville, Florida 32216, United States
  • Florida Inst For Clin Res LLC
    Orlando, Florida 32825, United States
  • Oviedo Medical Research, LLC
    Oviedo, Florida 32765, United States
  • Hope Clin Res & Wellness
    Conyers, Georgia 30094, United States
  • AMC Community Endocrinology
    Albany, New York 12203, United States
  • University of North Carolina
    Chapel Hill, North Carolina 27514, United States
  • PharmQuest Life Sciences LLC
    Greensboro, North Carolina 27408, United States
  • Amarillo Med Spec LLP
    Amarillo, Texas 79106, United States
  • Elligo Clin Res Centre
    Austin, Texas 78704, United States
  • Velocity Clin Res, Dallas
    Dallas, Texas 75230, United States
  • UT Southwestern Medical Center - Lingvay
    Dallas, Texas 75390, United States
  • PlanIt Research, PLLC
    Houston, Texas 77079, United States
  • DCOL Ctr for Clin Res
    Longview, Texas 75605, United States
  • Sugar Lakes Family Practice PA
    Sugar Land, Texas 77479, United States
  • National Clin Res Inc.
    Richmond, Virginia 23294, United States
  • Selma Medical Associates
    Winchester, Virginia 22601-3834, United States
  • MHAT - Blagoevgrad AD, Department of Internal Diseases
    Blagoevgrad, 2700, Bulgaria
  • IPSOMC - Dr. Georgi Marinov
    Burgas, 8000, Bulgaria
  • Medical Center Viva Feniks OOD
    Dobrich, 9300, Bulgaria
  • UMHAT Pulmed OOD - Pazardzhik, Department of Internal Diseases
    Pazardzhik, 4400, Bulgaria
  • MHAT Sveta Karidad EAD
    Plovdiv, 4004, Bulgaria
  • MHAT Hadzhi Dimitar OOD
    Sliven, 8800, Bulgaria
  • DCC VII - Sofia EOOD, Endocrinology
    Sofia, 1233, Bulgaria
  • UMHAT Prof. Dr. Stoyan Kirkovich AD
    Stara Zagora, 6003, Bulgaria
  • MHAT Sveti Panteleimon - Yambol AD
    Yambol, 8600, Bulgaria
  • Ocean West Research Clinic
    Surrey, British Columbia V3Z 2N6, Canada
  • G.A. Research Associates Ltd.
    Moncton, New Brunswick E1G 1A7, Canada
  • Nova Scotia Hlth Halifax
    Halifax, Nova Scotia B3H 1V7, Canada
  • Premier Clinical Trial Research Network (PCTRN)
    Hamilton, Ontario L8L 5G4, Canada
  • Wharton Medical Clinic Clinical Trials (Hamilton)
    Hamilton, Ontario L8L 5G8, Canada
  • Milestone Research
    London, Ontario N5W 6A2, Canada
  • Lausmed Kft.
    Baja, Bács-Kiskun county 6500, Hungary
  • Belinus Bt.
    Debrecen, Hajdú-Bihar 4025, Hungary
  • Borbánya Praxis E.Ü. Kft.
    Nyíregyháza, Szabolcs-Szatmar Varmegye 4405, Hungary
  • ClinDiab Egészségügyi Szolgáltató és Kereskedelmi Kft.
    Budapest, 1089, Hungary
  • Bajcsy-Zsilinszky Kórház
    Budapest, 1106, Hungary
  • MED-TIMA Kft.
    Budapest, 1132, Hungary
  • Fejér Megyei Szent György Oktatókórház
    Székesfehérvár, 8000, Hungary
  • Med. Cent. Diabet. Endo. Metabol. DIAB-ENDO-MET
    Krakow, Lesser Poland Voivodeship 31-261, Poland
  • NZOZ Przychodnia Specjalistyczna Medica
    Lublin, Lubelski 20-538, Poland
  • NZOZ "CenterMed Lublin" Sp. z o.o.
    Lublin, Lublin Voivodeship 20-044, Poland
  • Kresmed Sp. z o. o.
    Bialystok, Podlaskie Voivodeship 15-481, Poland
  • Centrum Medyczne Pratia Gdynia
    Gdynia, Pomeranian Voivodeship 81-338, Poland
  • Uniwersyteckie Centrum Kliniczne SUM w Katowicach
    Katowice, 40-752, Poland
  • NBR Polska Tomasz Klodawski
    Warsaw, 00-710, Poland
  • PANSTWOWY INSTYTUT MEDYCZNY MSWiA
    Warsaw, 02-507, Poland
  • ULS De Matosinhos E.P.E.- Hospital Pedro Hispano
    Senhora Da Hora, Matosinhos, Matosinhos 4464-513, Portugal
  • APDP - Associação Protectora dos Diabéticos de Portugal
    Lisbon, 1250-230, Portugal
  • Unidade Local De Saúde De Lisboa Ocidental E.P.E. - Hospital Egas Moniz
    Lisbon, 1349-019, Portugal
  • Hospital da Luz Lisboa, S.A.
    Lisbon, 1500-650, Portugal
  • ULS De São João, E.P.E. - Hospital de São João
    Porto, 4200-319, Portugal
  • Hospital da Luz Arrabida, S.A.
    Vila Nova de Gaia, 4400-346, Portugal
  • DIADA s.r.o.
    Bardejov, 08501, Slovakia
  • DIADA, s.r.o.
    Bardejov, 08501, Slovakia
  • Diab - Int, s.r.o.
    Bytča, 014 01, Slovakia
  • ENDOMED, s.r.o.
    Košice, 04013, Slovakia
  • MED-DIA CENTRUM s.r.o.
    Považská Bystrica, 01701, Slovakia
  • DIABETOL, s.r.o.
    Prešov, 080 01, Slovakia
  • Phoenix Pharma
    Port Elizabeth, Eastern Cape 6001, South Africa
  • Medi-Clinic Bloemfontein
    Bloemfontein, Free State 9301, South Africa
  • Soweto Clinical Trial Centre
    Johannesburg, Gauteng 1818, South Africa
  • Deepak Lakha
    Johannesburg, Gauteng 1820, South Africa
  • Hemant Makan
    Johannesburg, Gauteng 1827, South Africa
  • Wits Bara Clinical Trial Site
    Johannesburg, Gauteng 2013, South Africa
  • Maxwell Centre
    Durban, KwaZulu-Natal 4001, South Africa
  • Precise Clinical Solutions (Pty) Ltd
    Durban, KwaZulu-Natal 4092, South Africa
  • Dr N.K. Gounden Medical Centre
    Durban, KwaZulu-Natal 4093, South Africa
  • Lenmed Shifa Private Hospital
    Durban, KwaZulu-Natal 4901, South Africa
  • Dr T Padayachee
    eMkhomazi, KwaZulu-Natal 4170, South Africa
09

References and documents

Publications

  • Lingvay I, Bergenheim SJ, Buse JB, Freitas P, Garvey WT, Harder-Lauridsen NM, Rosenstock J, Sahu K, Wharton S; STEP UP T2D trial group. Once-weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025 Nov;13(11):935-948. doi: 10.1016/S2213-8587(25)00225-6. Epub 2025 Sep 14. PubMed 40961953 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisktrials.com

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Oct 2024, 21 months.

Results were first posted in Apr 2026, 1 year 5 months after primary completion. A results delay was requested in Oct 2025.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 21 months is close to that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2022
First posted
Dec 13, 2022
StartActual
Jan 4, 2023
Primary completionActual
Oct 28, 2024
CompletionActual
Dec 13, 2024
Results delay requested
Oct 20, 2025
Results first posted
Apr 27, 2026
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05649137
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Dec 13, 2022
Start date
Jan 4, 2023
Primary completion
Oct 28, 2024
Completion
Dec 13, 2024
Results posted
Apr 27, 2026
Last update
Apr 27, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion